A blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II
Authors:
- Jeffrey HarrisJHJeffrey Harris
- Yuda ZhuYZYuda Zhu
- Judy HoJHJudy Ho
- Charlene ChenCCCharlene Chen
- Anna BakardjievABAnna Bakardjiev
- Fabian ModelFMFabian Model
- Matthew TroyerMTMatthew Troyer
- Carole HoCHCarole Ho
- Peter ChinPCPeter Chin
- 3 February 2022
- journal article
- abstracts
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S55